Defence working to supply Accum to ADC companies

Executive Summary

• Defence Therapeutics is advancing its strategy to become a supplier of its proprietary Accum platform technology to ADC (antibody-drug conjugate) companies, aiming to solve dosing and toxicity issues in current cancer therapies.
• The company reported significant preclinical data showing that its Accum technology enhances the potency of existing ADCs, specifically demonstrating a ~20-fold increase in anti-tumour efficacy compared to the standard of care (Kadcyla) in mouse xenograft models.
• Following successful engagements at the World ADC Conference and CPHI in Frankfurt, Defence is actively engaging with pharmaceutical and biotech partners to license its technology for use across various antibodies and cancer indications.

Key Details

• Technology Platform: Defence’s proprietary "Accum" technology enables precision delivery of ADCs in their intact form to target cells, aiming to increase efficacy and potency while reducing toxicity.
• Preclinical Efficacy Data:
  • Model: Mouse xenograft models of HER2-positive breast cancer (JIMT-1 cells).
  • Comparison: Accum-Kadcyla vs. Kadcyla alone.
  • Dosage: Both administered at 0.5 milligram per kilogram.
  • Results: Accum-Kadcyla demonstrated approximately a 20-fold higher anti-tumour efficacy than Kadcyla alone.
  • Outcome: Tumour growth was significantly halted in the Accum-Kadcyla group, resulting in a consistent and near-complete response in 90% of the mice. Kadcyla alone at the same dose showed no effective results on inhibiting tumour growth.
• Strategic Engagements:
  • Conducted presentations and meetings at the World ADC Conference in San Diego.
  • Held meetings with industry leaders and pioneers at CPHI in Frankfurt.
  • Targeting ADC companies struggling with patient toxicity at therapeutic doses.
• Commercial Strategy: The technology is designed to be universal, capable of enhancing the potency of any ADCs, retaining epitope selectivity and tumour targeting, and applicable to any antibodies and indications.
• Management Commentary: Dr. Maxime Parisotto, Chief Scientific Officer, stated that many pharma/biotech companies face challenges with ADC toxicity, and Defence's technology can universally enhance potency while reducing toxicity.

Notable Quotes

• "Many pharmaceuticals and biotech companies have ADCs on the market or in development. A lot of these companies are facing the same challenge, their ADC being toxic for the patients at therapeutic dose. Defence's Accum technology can universally enhance the potency of any ADCs, reducing their toxicity, while retaining their epitope selectivity and tumour targeting," — Dr. Maxime Parisotto, Chief Scientific Officer.